We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-11.11%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.07B
AUM Growth
-$1.54B
Cap. Flow
-$210M
Cap. Flow %
-2.97%
Top 10 Hldgs %
34.72%
Holding
187
New
10
Increased
57
Reduced
82
Closed
15

Top Buys

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$67.9M
2
PFE icon
Pfizer
PFE
+$40.2M
3
CLDX icon
Celldex Therapeutics
CLDX
+$26.9M
4
HRMY icon
Harmony Biosciences
HRMY
+$26M
5
CRL icon
Charles River Laboratories
CRL
+$25.6M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$100M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$81.4M
3
ABBV icon
AbbVie
ABBV
+$47.5M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$47.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$45.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.26%
2 Industrials 0.38%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$362M 5.12%
9,776,528
-141,545
-1% -$5.34M
ARGX icon
2
argenx
ARGX
$53.8B
$350M 4.94%
933,803
-19,435
-2% -$6.26M
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$123B
$331M 4.69%
1,176,136
-304,117
-21% -$81.4M
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.2B
$277M 3.92%
2,844,305
-179,146
-6% -$16.5M
MRNA icon
5
Moderna
MRNA
$24.5B
$225M 3.19%
1,577,351
-61,998
-4% -$8.86M
INCY icon
6
Incyte
INCY
$23.4B
$211M 2.98%
2,773,377
-74,023
-3% -$5.62M
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$191M 2.7%
3,349,379
-80,240
-2% -$4.55M
ISRG icon
8
Intuitive Surgical
ISRG
$122B
$183M 2.58%
909,348
+289,280
+47% +$67.9M
ABT icon
9
Abbott
ABT
$175B
$171M 2.42%
1,573,807
-49,120
-3% -$5.58M
UNH icon
10
UnitedHealth
UNH
$387B
$155M 2.19%
302,044
-3,657
-1% -$1.84M
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$35.7B
$154M 2.18%
1,058,186
-171,377
-14% -$24.3M
BSX icon
12
Boston Scientific
BSX
$65.4B
$143M 2.03%
3,850,171
-63,776
-2% -$2.6M
JAZZ icon
13
Jazz Pharmaceuticals
JAZZ
$15.5B
$143M 2.02%
917,907
+162,926
+22% +$25.1M
AXNX
14
DELISTED
Axonics, Inc. Common Stock
AXNX
$131M 1.85%
2,313,852
+264,647
+13% +$14.5M
ELV icon
15
Elevance Health
ELV
$80.9B
$101M 1.42%
208,500
-203,137
-49% -$100M
EW icon
16
Edwards Lifesciences
EW
$49.4B
$96.1M 1.36%
1,010,627
+97,842
+11% +$10.1M
SAGE
17
DELISTED
Sage Therapeutics
SAGE
$96M 1.36%
2,973,178
-79,226
-3% -$2.66M
SYK icon
18
Stryker
SYK
$123B
$95M 1.34%
477,634
+37,409
+8% +$8.79M
DHR icon
19
Danaher
DHR
$144B
$92.3M 1.3%
410,633
+7,867
+2% +$1.81M
RDUS
20
DELISTED
Radius Health, Inc.
RDUS
$91.2M 1.29%
8,796,538
+477,824
+6% +$3.55M
AGIO icon
21
Agios Pharmaceuticals
AGIO
$2.36B
$90.1M 1.27%
4,062,792
-66,500
-2% -$1.5M
ARVN icon
22
Arvinas
ARVN
$517M
$89.4M 1.26%
2,124,276
-54,977
-3% -$2.76M
FATE icon
23
Fate Therapeutics
FATE
$324M
$88M 1.24%
3,550,086
-26,400
-0.7% -$728K
SRPT icon
24
Sarepta Therapeutics
SRPT
$1.82B
$85.4M 1.21%
1,139,455
-11,704
-1% -$861K
BDX icon
25
Becton Dickinson
BDX
$43.6B
$84.6M 1.2%
342,982
-63,333
-16% -$16.1M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2022 Portfolio in Review

As of Q2 2022, Bellevue Group held 187 positions worth $7.07B, down 18% from $8.61B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q2 2022 filing shows 10 new, 57 increased, 82 reduced and 15 closed positions. Its largest new stake was Celldex Therapeutics: 925,000 shares worth $24.9M. The largest sale was Elevance Health, an estimated $100M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q2 2022 buy was Celldex Therapeutics: 925,000 shares worth $24.9M.
  • Bellevue Group added most to Intuitive Surgical in Q2 2022, an estimated $67.9M increase.
  • Bellevue Group's biggest Q2 2022 reduction was Elevance Health, cutting an estimated $100M.
  • Bellevue Group fully exited Dentsply Sirona in Q2 2022, selling an estimated $7.83M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.07B portfolio in Q2 2022.
  • Bellevue Group opened 10 new positions and closed 15 in Q2 2022.
  • Bellevue Group's portfolio value fell 18% quarter-over-quarter to $7.07B.

Based on Bellevue Group's 13F filing for Q2 2022, filed 11 Aug 2022.